Techcyte's digital diagnostics platform applies the latest in convolutional neural networks to assist ARUP's staff in delivering fast and accurate results to doctors and patients.
The platform supports a range of whole slide scanners as well as multiple tests, such as blood differential, cervical cytology, fine needle aspiration, ova and parasites (fecal), urinalysis, and bacteriology.
The collaboration between ARUP and Techcyte will significantly accelerate the number of new test algorithms available to the lab diagnostic market.
ARUP's vast expertise and access to rare samples combined with Techcyte's data-pipeline and machine-learning experts will produce high-quality algorithms that can be developed quickly and then introduced into the market following thorough testing.
Medical labs, hardware manufacturers, hospitals, and clinics will all benefit from Techcyte's solutions. In 2019, Techcyte will deliver solutions for blood analysis, fecal ova and parasites, cervical cytology and bacteriology. Additional tests will be announced when they are ready for market use.
Headquartered in Orem, Utah, Techcyte, Inc. was founded in 2013 as a technology transfer from the University of Utah with a mission to lower healthcare costs through artificial intelligence.
Techcyte uses the power of deep machine learning to perform image analysis of whole slide images. Image analysis is required for widespread adoption of digital pathology in research, pharma, human, air quality and veterinary diagnostic testing.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development.
A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique lab tests, with accompanying consultative support, to enhance their abilities to provide laboratory services.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial